New investment paves the way for own production operations
Esslingen-based Amedrix GmbH receives investment totalling EUR 700,000
Amedrix GmbH develops and produces acellular implants based on a collagen type I matrix as medical products for various human and veterinarian purposes. The main advantage of these implants with regard to their intended application is how production can be varied concerning size, form and consistency. Furthermore, the collagen matrices are distinguished by excellent biocompatibility. In the body, the implants are settled by the patient's own cells which proliferate and assimilate their specific synthesis activity. Compared with cellsettled products already available on the market, this has the benefit that additional and expensive operations for cellwithdrawal are no longer necessary and long waiting periods for patients can be avoided. Amedrix GmbH has set up the technology for collagen and implant production and has tested first prototypes for functionality and biocompatibility.
"The main factors for the success of such products are improved medical options", comments Dr. Thomas Graeve, founder and managing director of Amedrix GmbH. "The quality of patients' care improves with the quality of medical products and their mode of application; minimally invasive operation methods are a good example to illustrate this". Costs for health insurance companies could be lowered significantly by using medical products in the field of regenerative medicine. "As this means that followup costs after especially complex treatments can be kept down, we do not expect to counter any resistance", explains Dr. Thomas Graeve convincingly.
The new financing now enables the company to take the necessary steps to obtain approval for its first products and then to set up production. Dr. Graeve is aiming at building up and developing a really strong business in the region with the widest possible spectrum of different medical implants.
Dr. Michael Nettersheim, Investment Manager of High-Tech Gründerfonds Management GmbH is convinced that "Amedrix hits the bull's eye on today's market with its closetomarket medical products. By reducing the number of necessary surgical interventions, Amedrix products are substantially cheaper in comparison to available products and a lot more pleasant for patients".
Stephan Reichstein, manager of the Life Science Fonds Esslingen, is in complete agreement: "This technology really convinces Life Science Fonds Esslingen. As urban business developers, we set great value not only on providing space but also the financial capital needed for the development of such a promising company as Amedrix GmbH. Investing in this company is an investment in the business location of Esslingen".
This view is echoed entirely by Managing Director of BioRegio STERN Management GmbH Dr. Klaus Eichenberg, who originally put Amedrix GmbH into contact with High-Tech Gründerfonds Management GmbH: "Amedrix GmbH is a key partner in our REGiNA project, which has the goal of promoting a User Centre for Regenerative Medicine. This investment reinforces our commitment to the Neckar-Alb and Stuttgart health region, and will ultimately bring great benefits for patients."
Amedrix GmbH was founded on 15 January 2009 in the Life Science Center Esslingen. Cell biologist Dr. Thomas Graeve is the company's Managing Director. Together with three employees, he is working on the development of innovative, acellular medical products based on animal collagen.
About High-Tech Gruenderfonds:
The High-Tech Gründerfonds invests venture capital in promising young, technology companies which use their innovative research results to set up a business. A seed financing of up to 500,000 EUR helps the startup companies to develop prototypes in their R&D projects, come up with "proofs of concept" or even launch a product. The High-Tech Gründerfonds has a fund volume of approx. 272 million EUR. Investors in this publicprivate partnership are the Federal Ministry of Economics and Technology, the KfW bank group as well as the six industrial concerns BASF, Deutsche Telekom, Siemens, Robert Bosch, Daimler and Carl Zeiss.
About LSF Esslingen:
The Life Science Fonds Esslingen GmbH & Co. KG was founded jointly by the city of Esslingen am Neckar, the business development department of the city of Esslingen, Kreissparkasse Esslingen-Nürtingen, Volksbank Esslingen as well as private investors as own venture capital fund.
This puts the city of Esslingen in a position to offer not only space for laboratories and offices but also venture capital, which is administered by the Life Science Fonds Esslingen Verwaltungs-GmbH. In particular the young biotechnology companies located in the Life Science Center Esslingen profit from this support.
BioRegio STERN Management GmbH
BioRegio STERN Management GmbH is a skillsharing network, providing a help and advice centre for founders of new businesses, entrepreneurs and researchers in the biotechnology sector in the region comprising Stuttgart, Tübingen, Esslingen, Reutlingen and Neckar-Alb in Germany. BioRegio STERN promotes cooperation between such different disciplines as medicine, biochemical engineering, sensor technology, dietetics, biochemical analysis and bioinformatics. Key areas of focus are regenerative medicine and medical technology. BioRegio STERN represents the interests of founders of new businesses, entrepreneurs and researchers when dealing with the political sector, the media and associations, coordinates economic promotional activities and marketing and provides advice for grant applications and corporate financing, all backed up with efficient press and public relations work. BioRegio STERN is supported by the Stuttgart and Neckar-Alb regional authorities and the municipal authorities of Stuttgart, Tübingen, Esslingen and Reutlingen. The Managing Director, Dr. Klaus Eichenberg, is a molecular and cell biologist and investment analyst.